公司新闻 | 关于罗氏 | 会员注册 | 医师沙龙 | 健康之家 | 联系我们 | 友情链接 |
用户名 密码验证码 请点击刷新验证码

全站搜索 
产品档案
 
首页：医师沙龙 >> 产品档案 >> Ｘ图书馆
请选择资料类别: 疾病种类： 
研究对象 有效率 用药剂量 其它用药 研究者
X QoL 2nd/3rd line MBC (8130) Stable or improved QoL 70% for most scales (none <60%). At least 40% of pts reported improvements from week 7 NA Segalla Brazil
phII AT sequential X adjuvant BC (782) Well tolerated capecitabine 1250 mg/m2 bid, day1-14, 21-day cycle x 6 doxorubicin 50 mg/m2 + docetaxel 75 mg/m2, day 1, 21-day cycle x 6 Lara Spain
phII XT neoadjuvant BC (752) 1,250 mg/m2 bid Docetaxel 75 mg/m2 d1/3w x4 cycles Bellet Spain
phIII AC vs XT stage II/III neoadjuvant BC (607) 87.9% A:2000mg/m2/daya A:TX x 4 (T 75 mg/m2 i.v. d1) B: AC x 4 (A 60mg/m2 i.v. d1/C 600 mg/m2 i.v. d1 q 3 wk) Lee Korea
32 advanced breast cancer 60% iv Navelbine: 25 mg/m2 on d1 and d 8 plus capecitabine: 825 mg/m2 twice a day from d1 to d14 every 3 weeks) followed by docetaxel: 35 mg/m2 weekly for 12 consecutive weeks Ghosn M et al
1234567891011121314151617181920212223242526272829303132
站点地图 | 隐私政策 | 法律声明 | 帮助信息
© 上海罗氏制药有限公司　版权所有
互联网药品信息服务资格证书编号：（沪）非经营性－2008－0017
沪ICP备05008670号